Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Related Content
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06

Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06

Martin David Harp
February 21st 2025
Article
Opthea Limited completes week 52 patient visits in the COAST trial

Opthea Limited completes week 52 patient visits in the COAST trial

Sydney M Crago
February 20th 2025
Article
PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611

PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611

Sydney M Crago
February 20th 2025
Article
The power of home monitoring

The power of home monitoring

Christina Y. Weng, MD, MBA
February 14th 2025
Article
Healthy lifestyles translate to lower risk of retinal disease

Healthy lifestyles translate to lower risk of retinal disease

Lynda Charters
February 14th 2025
Article
Opthea to present data from Phase 2b trial of sozinibercept at the Macula Society 48th Annual Meeting

Opthea to present data from Phase 2b trial of sozinibercept at the Macula Society 48th Annual Meeting

Sydney M Crago
February 13th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.